Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside

Impact · against what's priced in

Helus Pharma presents a highly asymmetric risk-reward profile based on the potential of HLP003. The current valuation significantly discounts the probability-weighted outcome of the upcoming Phase 3 APPROACH readout.

HELP+0.80

No priced-in read yet

In context

The current $269M EV is substantially lower than the $1.5B risk-adjusted implied value if the Phase 3 APPROACH readout in Q4 2026 is successful.

Read from the article alone

• pharmaceuticals
• biotech
• valuation
• HELP
• clinical trials
• depression
• fda
• phase 3
• psychedelics

Search tags